Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.72 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | CA1 | P00915 | 2/20 | 0.30 |
| ▸ | CA2 | P00918 | 2/20 | 0.30 |
| ▸ | CA9 | Q16790 | 2/20 | 0.30 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL836383 | 0.85 | LMNA (0.82) | LMNATSHRHDAC2KDM4ETDP1 | |
| SCHEMBL6562134 | 0.85 | LMNA (1.00) | LMNATSHRHDAC2KDM4ETDP1 | |
| SCHEMBL15298754 | 0.77 | LMNA (0.82) | LMNATSHRKDM4ETDP1POLB | |
| SCHEMBL14516809 | 0.75 | LMNA (0.78) | LMNATSHRHDAC2KDM4ETDP1 | |
| SCHEMBL24347595 | 0.75 | LMNA (0.78) | LMNATSHRKDM4ETDP1POLB | |
| SCHEMBL10064431 | 0.74 | — | — | |
| SCHEMBL12989977 | 0.73 | LMNA (0.75) | LMNATSHRHDAC2 | |
| SCHEMBL15895028 | 0.72 | — | — | |
| SCHEMBL10025171 | 0.71 | LMNA (0.69) | LMNATSHRHDAC2KDM4ETDP1 | |
| SCHEMBL26469358 | 0.71 | LMNA (0.69) | LMNATSHRKDM4ETDP1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8389697-B2 | Anthracycline derivative conjugates, process for their preparation and their use as antitumor compounds | GENENTECH, INC. (US) | 2013-03-05 | — | — | US | disclosed |
| US-20120130059-A1 | ANTHRACYCLINE DERIVATIVE CONJUGATES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS ANTITUMOR COMPOUNDS | BERIA ITALO (IT) | 2012-05-24 | — | — | US | disclosed |
| US-20110076287-A1 | NEMORUBICIN METABOLITE AND ANALOG REAGENTS, ANTIBODY-DRUG CONJUGATES AND METHODS | GENENTECH, INC. | 2011-03-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110076287-A1 | NEMORUBICIN METABOLITE AND ANALOG REAGENTS, ANTIBODY-DRUG CONJUGATES AND METHODS | BCR, CD79B, MYADM | LMNA 237/4885TSHR 1202/4885HDAC2 3315/4885 |
| US-20120130059-A1 | ANTHRACYCLINE DERIVATIVE CONJUGATES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS ANTITUMOR COMPOUNDS | MRPL21, BCR, MYD88 | LMNA 1429/4885TSHR 3353/4885HDAC2 3914/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.